Snakebites cause far more deaths worldwide than previously thought

A new analysis led by Dileepa Ediriweera and colleagues, published in PLOS Medicine on 25 August 2026, concludes that the global burden of snakebite has been substantially underestimated. The authors present a conservative estimate of about 2.1 million snake envenomings and 274,000 deaths per year. Their upper bound places annual envenomings at approximately seven million and deaths at up to 513,000.

These figures contrast sharply with the World Health Organization’s commonly cited range, which lists roughly 81,410 to 137,880 deaths annually from snakebite envenoming. The PLOS Medicine team argues that prior global estimates understate the true burden because of systematic underreporting, sparse surveillance systems and the integration of newer community‑based data sources into their modelling framework.

The paper is based on a systematic literature review and geostatistical modelling. The authors screened peer‑reviewed literature and grey sources covering the period 1 January 2007 to 31 March 2025. Ninety data sources were incorporated into the analysis—84 peer‑reviewed studies plus six web or agency datasets. Envenoming data from 79 countries went into a geostatistical Poisson model designed to estimate incidence and mortality across space while quantifying uncertainty.

A notable feature of the study is transparency: the authors published code and supporting files alongside the article, allowing others to inspect and reproduce key steps. The modelling framework aims to combine hospital records, community surveys and other datasets to address known gaps in formal reporting systems, particularly in rural settings where many victims never reach formal health services.

Several explanations underlie the divergence. First, many snakebite victims live in remote or impoverished areas and may never be recorded in official statistics. Deaths occurring outside healthcare facilities are often missed in national mortality systems. Second, the availability and standardisation of surveillance differ widely between countries, and in many regions no routine collection of snakebite data exists.

Third, community‑based studies—more common in recent years and included in the PLOS analysis—often report higher incidence than older, hospital‑based studies. By integrating these broader data sources and using spatial modelling to fill geographic gaps, the study produces higher global estimates. The authors also caution, however, that the wide uncertainty intervals reflect the variable quality and coverage of the underlying data.

The burden is concentrated in low‑income countries. According to the study, sub‑Saharan Africa accounts for roughly 45 percent of global envenomings and deaths. High incidence is also reported across South and Southeast Asia and in parts of Latin America. The geographic concentration has direct implications for how resources and international support should be allocated.

For local health systems already under strain, the consequences extend beyond acute fatalities. Snakebite survivors frequently face long‑term disabilities, including amputations and chronic sequelae, and the psychological impact on victims and families can be severe. Lack of reliable antivenom supply chains exacerbates mortality and morbidity, and the authors underline the need for both immediate emergency care improvements and sustained rehabilitation and prevention programs.

The study’s strengths include the breadth of data synthesis, use of open methods and a geostatistical framework that explicitly models uncertainty. These elements advance the field beyond point estimates based solely on sparse national reports. The public availability of code and supplementary materials also enhances reproducibility and invites further scrutiny.

Limitations remain. Model outputs necessarily depend on the quality and representativeness of input data. Community surveys can be affected by recall bias, hospital datasets are subject to selection bias, and grey literature varies in rigor. Some regions remain data‑poor, increasing reliance on model assumptions to interpolate burden. The authors explicitly acknowledge these caveats, arguing that despite uncertainty the results indicate a likely underestimation by previous global figures.

If even the lower bound of the PLOS estimates is accurate, global health priorities will need adjustment. A substantially larger burden argues for scaled‑up surveillance, better training of frontline staff in venomous bite management, expanded production and distribution of effective antivenoms, and support for long‑term rehabilitation services. The paper calls for standardised data collection protocols, more representative community studies, and research into antivenom effectiveness and supply chain resilience.

For European policymakers and donors, the implications are primarily in funding and technical support for endemic countries: strengthening epidemiological surveillance, enabling local antivenom manufacturing capacity, and supporting targeted prevention and education programs. The study highlights an area of neglected tropical disease that may demand far greater attention, coordination and resources than previously realised.